Immuno Cure BioTech
Hong Kong’s Immuno Cure completes $12M first close of Series A financing led by Gobi Partners
Hong Kong-based biotech firm Immuno Cure BioTech (Immuno Cure) announced Thursday that it has closed the $12 million tranche in the $27 million Series A fundraising round. Led by the AEF Greater Bay Area Fund that Gobi Partners GBA (Gobi GBA) manages, this round will be used to accelerate the development of DNA vaccines and antibodies, as well as to prepare…
